Physician profile
David C Dotson
NPI 1437148798
$4,340.08
in general payments reported to CMS, 2019-2025
24 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $211 · 2021: $390 · 2022: $1,349 · 2023: $563 · 2024: $534 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $978.60 | 2019-2022 | |
| Abbvie INC. | $671.39 | 2019-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $591.85 | 2019-2025 | Repatha, Otezla, Tepezza |
| Janssen Pharmaceuticals, INC | $430.25 | 2022-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.18 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $160.48 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $160.06 | 2021-2023 | Livalo, Seglentis |
| Novo Nordisk INC | $146.69 | 2022-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $137.43 | 2019-2020 | |
| Glaxosmithkline, LLC. | $130.18 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $107.39 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.87 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.48 | 2021-2024 | |
| Exact Sciences Corporation | $80.41 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $55.40 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $46.61 | 2019-2024 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $33.33 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $32.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.81 | 2024 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $17.70 | 2021 | |
| Alkermes, INC. | $16.92 | 2023 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $14.07 | 2019 | |
| Allergan, INC. | $13.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dotson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.